Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09SZY
|
||||
| Former ID |
DIB016563
|
||||
| Drug Name |
IQ-DAA
|
||||
| Synonyms |
Anti-anthrax toxin mAb, IQ; Human monoclonal antibodies (anthrax), IQ; IQN-protective antigen (human mAb), IQ corporation; MAb-based immunotherapy (anthrax), IQ; IQNLF + IQNPA (human mAbs, Bacillus anthracis infection), IQ Therapeutics
|
||||
| Indication | Bacillus anthracis infection [ICD10:A22] | Phase 1 | [1] | ||
| Company |
IQ Therapeutics BV
|
||||
| Target and Pathway | |||||
| Target(s) | Protective antigen | Target Info | Modulator | ||
| Lethal factor | Target Info | Modulator | |||
| Pathway Interaction Database | Cellular roles of Anthrax toxinanthraxpathway:Cellular roles of Anthrax toxin | ||||
| Reactome | Uptake and function of anthrax toxinsR-HSA-5210891:Uptake and function of anthrax toxins | ||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020942) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.